Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean‐Christophe Lagier, Matthieu Million, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 36, pp. 101791-101791
Open Access | Times Cited: 254

Showing 1-25 of 254 citing articles:

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
Post-COVID Syndrome: An Insight on Its Pathogenesis
Helena C. Maltezou, Androula Pavli, Athanassios Tsakris
Vaccines (2021) Vol. 9, Iss. 5, pp. 497-497
Open Access | Times Cited: 201
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
Peter A. McCullough, Ronan J. Kelly, Gaetano Ruocco, et al.
The American Journal of Medicine (2020) Vol. 134, Iss. 1, pp. 16-22
Open Access | Times Cited: 162
Immune responses during COVID-19 infection
Cléa Melenotte, Aymeric Silvin, Anne-Gaëlle Goubet, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 146
Natural history of COVID-19 and therapeutic options
Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 12, pp. 1159-1184
Closed Access | Times Cited: 143
Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis
Endang Mutiawati, Marhami Fahriani, Sukamto S. Mamada, et al.
F1000Research (2021) Vol. 10, pp. 40-40
Open Access | Times Cited: 113
Factors associated with the spatial heterogeneity of the first wave of COVID-19 in France: a nationwide geo-epidemiological study
Jean Gaudart, Jordi Landier, Laëtitia Huiart, et al.
The Lancet Public Health (2021) Vol. 6, Iss. 4, pp. e222-e231
Open Access | Times Cited: 110
Asymptomatic hypoxia in COVID-19 is associated with poor outcome
Philippe Brouqui, Sophie Amrane, Matthieu Million, et al.
International Journal of Infectious Diseases (2020) Vol. 102, pp. 233-238
Open Access | Times Cited: 124
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
Lucy Catteau, Nicolás Dauby, Marion Montourcy, et al.
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 4, pp. 106144-106144
Open Access | Times Cited: 121
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, et al.
European Journal of Internal Medicine (2020) Vol. 82, pp. 38-47
Open Access | Times Cited: 110
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
Mathieu Gendrot, Julien Andréani, Manon Boxberger, et al.
Travel Medicine and Infectious Disease (2020) Vol. 37, pp. 101873-101873
Open Access | Times Cited: 99
In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2
Mathieu Gendrot, Julien Andréani, Priscilla Jardot, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 5064-5064
Open Access | Times Cited: 87
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium
Fabio Silvio Taccone, Nina Van Goethem, Robby De Pauw, et al.
The Lancet Regional Health - Europe (2020) Vol. 2, pp. 100019-100019
Open Access | Times Cited: 83
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
Peter A. McCullough, Paul Alexander, Robin Armstrong, et al.
Reviews in Cardiovascular Medicine (2020) Vol. 21, Iss. 4
Open Access | Times Cited: 80
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world
Matthieu Million, Philippe Gautret, Philippe Colson, et al.
New Microbes and New Infections (2020) Vol. 38, pp. 100709-100709
Open Access | Times Cited: 71
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Robert J. Ulrich, Andrea B. Troxel, Ellie Carmody, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 10
Open Access | Times Cited: 69
Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis
Yueyang Zhong, Kai Wang, Yanan Zhu, et al.
Travel Medicine and Infectious Disease (2021) Vol. 44, pp. 102191-102191
Open Access | Times Cited: 63
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
Christine Johnston, Elizabeth R. Brown, Jenell Stewart, et al.
EClinicalMedicine (2021) Vol. 33, pp. 100773-100773
Open Access | Times Cited: 62
Long-term persistence of olfactory and gustatory disorders in COVID-19 patients
Nhu Ngoc Nguyen, Van Thuan Hoang, Jean‐Christophe Lagier, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 6, pp. 931-932
Open Access | Times Cited: 61
COVID‐19 re‐infection
P. Brouqui, Philippe Colson, Cléa Melenotte, et al.
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 5
Open Access | Times Cited: 58
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
Ali S. Omrani, Sameer A. Pathan, Sarah A. Thomas, et al.
EClinicalMedicine (2020) Vol. 29-30, pp. 100645-100645
Open Access | Times Cited: 66
COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2
Ling Xu, Dandan Yu, Yuhua Ma, et al.
动物学研究 (2020) Vol. 41, Iss. 5, pp. 517-526
Open Access | Times Cited: 63
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
Abdullahi Rabiu Abubakar, Ibrahim Sani, Brian Godman, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 4673-4695
Open Access | Times Cited: 61
Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19
Jacques Fantini, Henri Chahinian, Nouara Yahi
Biochemical and Biophysical Research Communications (2020) Vol. 538, pp. 132-136
Open Access | Times Cited: 54
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
Bianza Moïse Bakadia, Feng He, Tiatou Souho, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 133, pp. 111008-111008
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top